Table 1.
Patient characteristics of the training and validation cohort.
| Training Cohort | Validation Cohort | p-Value | |
|---|---|---|---|
| n | 206 | 285 | |
| Age, years (median [IQR]) | 58.66 [49.30, 67.22] | 55.00 [42.00, 63.00] | <0.001 |
| BMI, kg/m2 (median [IQR]) | 23.61 [20.80, 27.12] | 23.30 [20.60, 26.35] | 0.699 |
| Male gender (%) | 129 (62.6) | 161 (56.5) | 0.204 |
| Proven IA (%) | 32 (15.5) | 13 (4.6) | <0.001 |
| Bilirubin, mg/dL (median [IQR]) | 0.66 [0.47, 0.97] | ||
| Creatinine, mg/dL (median [IQR]) | 0.70 [0.54, 1.03] | ||
| Neutrophils/µL (median [IQR]) | 0 [0, 845] | ||
| Monocytes/µL (median [IQR]) | 0 [0, 100] | ||
| Platelets/µL (median [IQR]) | 39,000 [20,250, 71,500] | ||
| Active GvHD (%) | 28 (13.7) | ||
| High dose corticosteroids * (%) | 46 (22.4) | ||
| Initial antifungal therapy (%) | |||
| Azole | 113 (54.9) | ||
| Echinocandin | 48 (23.3) | ||
| Polyene | 32 (15.5) | ||
| Combination | 11 (5.3) | ||
| Other | 2 (1.0) |
* Defined as prednisone-equivalent dose of 0.3 mg/kg/day for 21 days. IQR = Interquartile range. BMI = Body mass index. IA = Invasive aspergillosis. GvHD = Graft-versus-host disease.